Gore, Martin

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 7,774

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 1,260

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 592

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

Diem, S., Kasenda, B., Spain, L., Martin-Liberal, J., Marconcini, R., Gore, M., & Larkin, J. (2016) · British Journal of Cancer

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 308

Vessel Co-option Is Common in Human Lung Metastases and Mediates Resistance to Anti-angiogenic Therapy in Preclinical Lung Metastasis Models

Bridgeman, V. L., Vermeulen, P. B., Foo, S., Bilecz, A., Daley, F., Kostaras, E., Nathan, M. R., Wan, E., Frentzas, S., Schweiger, T., et al. (2017) · The Journal of Pathology

Angiogenesis and VEGF in CancerCancer Cells and Metastasis

Cited by 214

Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma

Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology

Cancer Immunotherapy and BiomarkersThyroid Disorders and Treatments

Cited by 190

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y., de Jonge, M., Hong, S. H., Park, Y. H., Wolfer, A., Brown, J., Ferguson, M., Gore, M. E., Alvarez, R. H., Gresty, C., et al. (2018) · Gynecologic Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 131

Adverse effects of gene therapy: gene therapy can cause leukaemia: no shock, mild horror but a probe

Gore, M. E. (2003) · Gene Therapy

Virus-based gene therapy researchCAR-T cell therapy research

Cited by 53

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., et al. (2021) · Annals of Oncology

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 21